J&J Pharma R&D Taps Entelos for In Silico Studies of Type-2 Diabetes Therapies

Dec 19, 2007

NEW YORK (GenomeWeb News) - Entelos said today that has signed an agreement with Johnson & Johnson Pharmaceutical Research & Development to use its predictive computer models of human physiology to study new therapies for type-2 diabetes.

Under the agreement, Entelos will use its in silico “virtual patients” to discover and evaluate therapies for the disease.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

No Flu for These Birds

Reuters reports that UK researchers are using gene-editing tools to develop flu-resistant chickens.

To Track Cholera

Nature calls for genomics to become part of the World Health Organization's cholera surveillance approach.

Better Odds?

Vox explores a proposal to institute a lottery system to award grant funds.

This Week in Genome Biology

In Genome Biology this week: gut microbiome study of individuals from Tanzania and Botswana, sixth version of the Network of Cancer Genes database, and more.

Main menu